<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mechlorethamine (nitrogen mustard) topical gel: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mechlorethamine (nitrogen mustard) topical gel: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Mechlorethamine (nitrogen mustard) topical gel: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="91065" href="/d/html/91065.html" rel="external">see "Mechlorethamine (nitrogen mustard) topical gel: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F21963627"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Valchlor</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F57401757"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Ledaga</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F21963128"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Alkylating Agent;</li>
<li>
                        Antineoplastic Agent, Alkylating Agent (Nitrogen Mustard)</li></ul></div>
<div class="block doa drugH1Div" id="F21963184"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a2d2200c-1185-4212-93d2-1ced9a8fa5fe">Cutaneous T-cell lymphoma, mycosis fungoides-type</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cutaneous T-cell lymphoma, mycosis fungoides-type:</b>
<b>Topical:</b> Apply a thin film once daily to affected areas of skin. In the clinical study, treatment was continued for 1 year and concurrent use of topical or systemic corticosteroids was not allowed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23069814']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23069814'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990175"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, based on the lack of systemic exposure, dosage adjustment is likely not necessary.</p></div>
<div class="block doha drugH1Div" id="F50987566"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, based on the lack of systemic exposure, dosage adjustment is likely not necessary.</p></div>
<div class="block dot drugH1Div" id="F21963188"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">Skin ulceration (any grade), blistering, or dermatitis (moderately severe-to-severe): Withhold treatment; upon improvement, may reinitiate treatment with a reduced frequency of once every 3 days; if every 3-day application is tolerated for at least 1 week, may increase to every other day for at least 1 week, then (if tolerated) may increase to once daily.</p></div>
<div class="block doe drugH1Div" id="F21963185"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F21982693"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatitis (56%; moderately severe or severe: 23%), pruritus (20%), bacterial skin infection (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hematologic abnormality (decreased hemoglobin, neutrophils, or platelets; 13%) </p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermal ulcer (6%), skin hyperpigmentation (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Malignant neoplasm (nonmelanoma skin cancer; 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing and/or case reports: Anaphylaxis, hypersensitivity reaction</p></div>
<div class="block coi drugH1Div" id="F21963133"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known severe hypersensitivity to mechlorethamine or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F21963134"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Accidental exposure: Eye exposure may result in pain, burning, inflammation, photophobia, and blurred vision. Blindness and severe anterior eye injury (irreversible) may occur. If exposure to eye(s) occurs, promptly irrigate for at least 15 minutes with copious amounts of water, normal saline, or balanced salt ophthalmic irrigating solution; obtain immediate medical care, including ophthalmology consultation. Exposure to mucous membranes may cause pain, redness, and ulceration; may be severe. If mucosal contact occurs, irrigate promptly for at least 15 minutes with copious amounts of water and obtain medical consultation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatitis: Dermatitis commonly occurs; may be moderately severe or severe. Symptoms include redness, swelling, itching, blistering, ulceration, and secondary skin infections. Facial, genitalia, anus and intertriginous skin areas are at increased risk for dermatitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions (including anaphylaxis) have occurred with topical mechlorethamine application.</p>
<p style="text-indent:-2em;margin-left:4em;">• Secondary exposure: Avoid direct contact with mechlorethamine (other than intended treatment areas for the patient). Secondary exposure risks include dermatitis, mucosal injury, and secondary malignancies. To prevent secondary exposure, follow recommended application procedures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Secondary malignancy: In a clinical study, nonmelanoma skin cancers developed during or within 1 year following treatment. Some instances occurred in patients who had received previous treatments that were associated with nonmelanoma skin cancer. Nonmelanoma skin cancers may occur anywhere on the skin, including untreated areas.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Flammable gel: Mechlorethamine gel contains alcohol and is flammable; follow recommended application procedures and avoid fire, flame, and smoking until mechlorethamine has dried.</p></div>
<div class="block dosfc drugH1Div" id="F21963194"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Valchlor 0.016% is equivalent to 0.02% mechlorethamine hydrochloride</p></div>
<div class="block foc drugH1Div" id="F22370039"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Valchlor: 0.016% (60 g) [contains edetate (edta) disodium, isopropyl alcohol, menthol, propylene glycol]</p></div>
<div class="block geq drugH1Div" id="F21963127"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F23613364"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Valchlor External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.016% (per gram): $113.45</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F57401758"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ledaga: 0.016% (60 g) [contains edetate (edta) disodium, isopropyl alcohol, menthol, propylene glycol]</p></div>
<div class="block accres drugH1Div" id="F21963125"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Valchlor is only available through a specialty pharmacy; information regarding prescribing and access may be found at www.valchlor.com.</p></div>
<div class="block adm drugH1Div" id="F21963190"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Topical:</b> Apply a thin film topically to affected area. Apply immediately (or within 30 minutes) after removal from refrigerator; return to refrigerator promptly after each use. Apply to completely dry skin at least 4 hours before or 30 minutes after showering/washing. Allow treated area(s) to dry for 5 to 10 minutes after application before covering with clothing. May apply emollients (moisturizers) to treated area 2 hours before or 2 hours after mechlorethamine application. Do not use occlusive dressings over treatment areas. Avoid fire, flame, and smoking until mechlorethamine has dried.</p>
<p style="text-indent:0em;margin-top:2em;">Caregivers should wear nitrile gloves when applying to patients. Wash hands thoroughly with soap and water after handling/application. If accidental skin exposure occurs, wash thoroughly for at least 15 minutes with soap and water; remove any contaminated clothing.</p></div>
<div class="block hazard drugH1Div" id="F49132668"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block meg drugH1Div" id="F21654318"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Valchlor: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F202317s009lbl.pdf%23page%3D10&amp;token=F1Fise%2FwoXWP3rWu3m1d8mDxVQZkhWUklDMzwkB3ATWIAIg7YvcvNQlBsXdeMuL%2FL32kfoRitl3XULuyMnHPx2mpKHncKii7dDjQLwdbWzIex%2F5%2FsC4TFX7QHZ0hce7B&amp;TOPIC_ID=91010" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202317s009lbl.pdf#page=10</a></p></div>
<div class="block use drugH1Div" id="F21313055"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Cutaneous T-cell lymphoma, mycosis fungoides-type:</b> Topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.</p></div>
<div class="block cyt drugH1Div" id="F21989925"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F21989923"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F53578106"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Patients are advised not to become pregnant during topical mechlorethamine treatment. Patients who could become pregnant and patients with partners who could become pregnant should use a barrier method of contraception during therapy.</p></div>
<div class="block pri drugH1Div" id="F21963130"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action, case reports in humans, and data from animal reproduction studies, in utero exposure to topical mechlorethamine may cause fetal harm. There are case reports of major birth defects following maternal administration of systemic mechlorethamine.</p></div>
<div class="block brc drugH1Div" id="F21963132"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if mechlorethamine is present in breast milk following topical application.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant following topical or systemic exposure from the mother's skin, the manufacturer recommends a decision be made to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F21963192"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for dermatologic toxicity (skin ulcers, blistering, dermatitis, secondary skin infections), and for signs/symptoms of nonmelanoma skin cancer (during treatment and after discontinuation) and/or hypersensitivity reactions.</p></div>
<div class="block pha drugH1Div" id="F21963178"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Mechlorethamine is a nitrogen mustard alkylating agent which forms inter- and intra-strand DNA cross-links, resulting in inhibition of DNA synthesis. Topical application allows for skin-directed treatment while minimizing systemic nitrogen mustard exposure (Lessin 2013).</p></div>
<div class="block phk drugH1Div" id="F21963180"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Topical: None detected (Lessin 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Topical: No detectable systemic exposure in a clinical study (Lessin 2013).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58209989"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ledaga</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ledaga</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Ledaga</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ledaga</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ledaga</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ledaga</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ledaga</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ledaga</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Ledaga</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ledaga</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ledaga</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ledaga</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ledaga</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Valchlor</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ledaga</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ledaga</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Ledaga</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.2020">
<a name="USP.2020"></a>&lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23069814">
<a name="23069814"></a>Lessin SR, Duvic M, Guitart J, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. <i>JAMA Dermatol</i>. 2013;149(1):25-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mechlorethamine-nitrogen-mustard-topical-gel-drug-information/abstract-text/23069814/pubmed" id="23069814" target="_blank">23069814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.2016">
<a name="NIOSH.2016"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Valchlor.1">
<a name="Valchlor.1"></a>Valchlor (mechlorethamine) [prescribing information]. Iselin, NJ: Helsinn Therapeutics (U.S.), Inc; January 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 91010 Version 225.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
